Influenza A virus neuraminidase mRNA (NA mRNA)

Influenza A virus neuraminidase (NA) mRNA is the messenger RNA transcript derived from segment 6 of the viral genome, serving as the template for the synthesis of the neuraminidase enzyme (Source: NCBI, TaxID: 11320). The encoded neuraminidase is a membrane-bound sialidase that plays a vital role in the viral life cycle by cleaving sialic acid receptors, which allows newly synthesized virions to be released from the host cell and prevents their sequestration by mucus in the respiratory tract (Source: Shtyrya et al., 2009, Acta Naturae). While traditional influenza therapies like oseltamivir target the neuraminidase protein's active site, targeting the NA mRNA transcript offers a pre-translational approach to viral inhibition (Source: Ge et al., 2003, Nature Medicine). Therapeutic modalities such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are designed to bind to conserved sequences within the NA mRNA, leading to its degradation or the blocking of translation (Source: Tompkins et al., 2004, PNAS). This approach aims to provide broad-spectrum protection against multiple influenza strains and reduce the emergence of drug resistance by focusing on regions of the viral genome that are essential and highly conserved (Source: Zhou et al., 2007, Antiviral Research). Experimental candidates like ALN-FLU have demonstrated the feasibility of this strategy in reducing viral replication in vivo (Source: Alnylam Pharmaceuticals).

Other names

Neuraminidase messenger RNAInfluenza A virus segment 6 mRNANA transcriptInfluenza A virus segment 6

Inhibition of viral protein synthesis through sequence-specific degradation of mRNA (RNA interference) or steric hindrance of the translation machinery (antisense oligonucleotides), preventing the expression of the neuraminidase enzyme (Source: Ge et al., 2003; Tompkins et al., 2004).